Acer Therapeutics — Investor Presentation (October 2019)
41 slides from Acer Therapeutics's investor presentation, Oct 29, 2019
Slide 1: Corporate Presentation October 2019
Developing Therapeutics for the Treatment of Serious Rare and Life-Threatening Diseases with Critical Unmet Medical Needs Corporate Presentation October 2019 Nasdaq: ACER Exhibit 99.1
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in
Slide 3: Corporate Overview
Corporate Overview Acer Therapeutics is a pharmaceutical company that acquires, develops and seeks to commercialize therapies for serious rare and life-threatening diseases with critical unmet medical needs Headquartered: Newton, MA Headcount: 17 Founded: December 2013 Public: September 2017 Cash: $
Slide 4: Executive Leadership Team
Executive Leadership Team Chris Schelling CEO & Founder 20 years; strategic commercial development & orphan Will Andrews, MD Chief Medical Officer 20 years; clinical development, medical affairs & orphan M.D. Yale University School of Medicine Matt Seibt Chief Commercial Officer 22 years; sales, mar
Slide 5: Investment Highlights
Investment Highlights Acer’s pipeline includes three clinical-stage product candidates: EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation ACER-001 (a fully taste-masked, immediate release formulation of s
Slide 6: Clinical Pipeline
Program / Indication Novel MOA / Unique Characteristics Phase 1 Phase 2 Phase 3 NDA Market EDSIVOTM (celiprolol) vascular Ehlers-Danlos syndrome (COL3A1+)* Induces vascular dilatation and smooth muscle relaxation ACER-001 (taste-masked, immediate-release form of sodium phenylbutyrate) Urea Cycle Dis
Slide 7: EDSIVO has a unique pharmacological profile
EDSIVO™ has a unique pharmacological profile β2 and β3 adrenergic receptor agonist; selective β1 and ⍺2 adrenergic receptor antagonist; activates endothelial Nitric Oxide Synthase (eNOS) EDSIVO’s™ potential beneficial effects in vEDS thought to be through vasodilation and vascular smooth muscle dila
Slide 8: EDSIVO: CRL and Next Steps
Received CRL from FDA on June 24, 2019 stating that it will be necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS Acer is working with Hyman, Phelps, & McNamara (HPM) and other leading industry experts
Slide 9: EDSIVO: CRL and Next Steps (FDA appeal outcomes)
In 2016, FDA published that from 2003-2014, of the 140 appeals accepted, 16% were granted and 84% denied. According to HPM, these “denials” are most often “wins” While approval is not provided based on the previous NDA submission, the company is given a more favorable path forward to approval than w
Slide 10: EDSIVO: CRL and Next Steps (Type A meeting)
FDA Type A meeting held October 7, 2019 Acer is considering the potential to submit a Formal Dispute Resolution Request (FDRR) to the Office of New Drugs (OND) The entire process will likely take many months and possibly a year or more to reach final outcome We will provide updates as appropriate an
Slide 11: Vascular Ehlers-Danlos Syndrome (vEDS)
Ehlers-Danlos syndrome (EDS) is a group of hereditary disorders of connective tissue vEDS (EDS type IV) is the severe subtype: Characterized by aneurysms, dissections and/or ruptures Vascular Gastrointestinal Uterine Autosomal dominant (50%); spontaneous mutations (50%) Diagnosed by clinical symptom
Slide 12: EDSIVO Unique Mechanism of Action
Cardiology in Review 2017;25: 247–253. * Hypertension 2003 Nov;42(5):1004-13. EDSIVO™ has a unique pharmacological profile: β2 and β3 adrenergic receptor agonist Selective β1 and ⍺2 adrenergic receptor antagonist Intrinsic sympathomimetic activity (ISA+) Lacks non-specific membrane effects Activates
Slide 13: EDSIVO BBEST Pivotal Clinical Trial
Efficacy: 64% reduction in the average risk of fatal or nonfatal cardiac or arterial events in EDSIVO™ patients vs. control group over mean follow-up of 47 months 76% average reduction in risk of fatal or nonfatal cardiac or arterial events in COL3A1+ EDSIVO™ patients vs. control group 69% reduction
Slide 14: Efficacy: celiprolol survival data
Efficacy: Between 2000 and 2017, 144 patients (median age at diagnosis 34.5 years; 100% COL3A1+) were included in this study (A) Patients not treated with celiprolol had a significantly worse survival outcome than treated patients: Overall survival was 80.7% (95% CI: 67.8% to 93.6%) in those treated
Slide 15: EDSIVO U.S. vs. French vEDS Patients
EDSIVO™ U.S. vs. French vEDS Patients Pepin Genet Med. 2014 Dec;16(12):881-8. Frank et al., J Am Coll Cardiol. 2019 Apr 23;73(15):1948-1957. Median Survival: 51 years (46 y.o. males; 54 y.o. females) U.S. vEDS Natural History 1,231 patients (>90% COL3A1+; 630 index / 601 relatives) French vEDS Popul
Slide 16: Antihypertensive use in U.S. vEDS patients
Background: No currently approved medications to treat vEDS There is no evidence supporting the use of antihypertensive medications in vEDS Methods: Retrospective analysis of U.S. insurance claims identifying vEDS patients 2014-2017 Patient data stratified based on claims for patients taking antihyp
Slide 17: ACER-001: taste-masked sodium phenylbutyrate
Small molecule with unique MOAs in various disorders UCDs: NaPB is a prodrug of phenylacetate, a NH4+ scavenger MSUD: NaPB is an allosteric inhibitor of BCKD kinase UCDs: A group of metabolic genetic diseases that lead to toxic build-up of NH4+ UCDs: Currently treated with RAVICTI®, BUPHENYL®, AMMON
Slide 18: UCDs: Clinical Manifestations
Newborns with severe urea cycle disorders become catastrophically ill with symptoms that mimic sepsis -- failure to feed, lethargy, respiratory distress, seizures and ultimately coma Children and adults with milder (or partial) urea cycle enzyme deficiencies may go years without a diagnosis, until a
Slide 19: ACER-001 UCDs: Unmet Need
ACER-001 UCDs: Unmet Need BUPHENYL®: Foul odor and foul/bitter taste; considered unpalatable* 64% of patients reported it is difficult to take because of taste Physicians reported that 25-33% of patients were prescribed less than target dose due to tolerability Only 25% of patients indicated that th
Slide 20: ACER-001: Taste-masked, IR Formulation
Mouth → Stomach Protection for several minutes at mouth pH followed by rapid release at stomach pH ACER-001 ACER-001: Taste-masked, IR Formulation TM coat (Eudragit E) Seal coat (HPMC) Drug layer (NaPB, HPMC) Seed core (microcrystalline cellulose) Expected drug loading maximum ~50% ~400µm Drug Layer
Slide 21: ACER-001: Differentiation
Phenylbutyrate Formulations ACER-001* RAVICTI® BUPHENYL® Efficacy / Safety in UCDs ✓ ✓ ✓ Palatability / Compliance ✓ ✓ ✘ ** Pricing (Per Patient Per Year) TBD, likely near BUPHENYL $158k-$1.2M*** $204k-$402k*** Formulation Multi-Particulate Beads (Sachet) Oil (Tablespoons) Powder/Tablets (up to 40 t
Slide 22: Pivotal bioavailability and bioequivalence trial
Pivotal bioavailability and bioequivalence (BE) trial: Part A: single-center, single-blind, randomized, single-dose crossover trial designed to evaluate bioavailability of three different oral suspension formulations of ACER-001 compared to BUPHENYL® in 20 healthy adult subjects Fully enrolled in Oc
Slide 23: UCDs: Market Opportunity
UCDs: Market Opportunity Target existing Rx market share in UCDs Currently 1,100 patients diagnosed with ~600 patients on Rx therapy* 2018 U.S. revenue for Ravicti® & Buphenyl® = $248.4M Goal: transition patients from Ravicti® & Buphenyl® to ACER-001 and capture a portion of new UCDs Rx “Transition”
Slide 24: Maple Syrup Urine Disease (MSUD)
MSUD is an inborn error of Branched-chain Amino Acid (BCAA) – leucine, isoleucine, valine – metabolism Caused by deficiency of the mitochondrial Branched-chain Keto Acid Dehydrogenase complex (BCKDC) ~800 patients in U.S., ~3,000 patients worldwide MSUD Family Support Group has >500 patients Part of
Slide 25: ACER-001 MSUD: Clinical POC
ACER-001 MSUD: Clinical POC Study Design: Open label pilot study1 at BCM – 3 healthy and 5 MSUD subjects with late onset disease 3 days of steady-state protein diet*; then 3 days of NaPB + diet* BCAAs and BCKAs determined at day 3 of each study period (4 time points) Results: NaPB demonstrated stati
Slide 26: MSUD: Market Opportunity
MSUD: Market Opportunity About 1,000 MSUD patients in the U.S., ~3,000 WW* 20-25% MSUD patients in U.S. are Mennonite; incidence up to 1/380 Ashkenazi Jewish population; incidence of 1/26,000 No treatments currently approved for MSUD ACER-001 granted U.S. Orphan Drug status by FDA Early treatment ma
Slide 27: ACER-001: Exclusivity / IP
ACER-001 ACER-001: Exclusivity / IP Filed formulation patent application (filed Oct. 2016) Issued patents (US/EP): “Methods of modulation of branched chain acids and uses thereof” [US PATENT NO. 10,092,532] in MSUD Exclusive license rights from Baylor College of Medicine UCDs: 505(b)(2) application
Slide 28: Osanetant: NK3 receptor antagonist for iVMS
Osanetant is a selective, non-peptide tachykinin NK3 receptor antagonist NK3R is the main receptor for neurokinin B (NKB), a tachykinin peptide primarily found in the arcuate nucleus (ARC) of the hypothalamus iVMS: Induced Vasomotor Symptoms where Hormone Replacement Therapy (HRT) is likely contrain
Slide 29: Osanetant History
Acer acquired worldwide rights to osanetant from Sanofi in January 2019 Osanetant (SR142801) was the first selective non-peptide tachykinin NK3 receptor antagonist evaluated as a potential treatment for schizophrenia Clinical and laboratory safety results are available from 21 completed Phase 1 and
Slide 30: Vasomotor Symptoms (VMS): Overview
VMS, typically comprised of hot flashes and night sweats, are associated with decreases in reproductive hormones commonly associated with menopause (e.g. MR-VMS) While VMS associated with menopause can often be treated with hormone replacement therapy (HRT), there are patients who experience VMS who
Slide 31: Osanetant Induced Vasomotor Symptoms (iVMS)
Osanetant Induced Vasomotor Symptoms (iVMS) Women with HR+ Breast Cancer (CaB) receiving Tamoxifen 84% of women experienced hot flashes1 80% experienced night sweats 60% experienced severe symptoms Symptoms persisted throughout 5 years of treatment and were mainly attributed to tamoxifen After 4.5 y
Slide 32: Osanetant iVMS: The Unmet Need
Osanetant iVMS: The Unmet Need Induced vasomotor symptoms (iVMS) are well documented with the use of hormonal cancer therapies and certain surgical procedures Symptoms such as hot flashes can appear immediately and be severe Traditional HRTs are usually contraindicated Non-adherence to therapy can b
Slide 33: NK3 Receptor (Neurokinin B)
Neurokinin B (NKB) belongs to a group of neuropeptides, called tachykinins or neurokinins, that includes substance-P (SP), neurokinin A (NKA), and two N-terminally extended forms of NKA, neuropeptide g and neuropeptide K The biological effects of tachykinins are mediated through specific receptors d
Slide 34: Osanetant VMS: Mechanism of Action
Neurons in the arcuate nucleus of the hypothalamus that express kisspeptin and neurokinin B (Kiss1ARH neurons) are candidates for mediating hot flushes because they are negatively regulated by sex hormones Transient activation of Kiss1ARH neurons following sex-hormone withdrawal contributes to the o
Slide 35: NK3R Antagonist Clinical POC in VMS (fezolinetant)
Osanetant NK3R Antagonist Clinical POC in VMS Herman Depypere et al., ENDO2017 Fezolinetant is a NK3R antagonist being developed by Astellas At Week 4: fezolinetant group: 14/40 patients have ZERO hot flash placebo group: 2/40 patients have ZERO hot flash Average Daily Hot Flash Frequency Reported a
Slide 36: NK3R Antagonist Clinical POC in VMS (pavinetant)
Osanetant NK3R Antagonist Clinical POC in VMS Prague J., et al. Menopause. 2018 Aug;25(8):862-869. Pavinetant (MLE4901) was a NK3R antagonist that was discontinued by Millendo % change from baseline Hot flash frequency Hot flash severity Placebo MLE4901 Hot flash bother Hot flash interference A B C
Slide 37: Osanetant: Clinical Development Plan
Acer is partnering with a leading university to design & conduct a clinical trial to evaluate osanetant in various patient populations with iVMS These include patients with medically or surgically iVMS (may include any/all of the following): Women who are BRCA+ and have had a prophylactic bilateral
Slide 38: Competitive Landscape
Competitive Landscape Osanetant Program / Company Indication MOA Status VERU-944 (Veru) iVMS in PC on ADT ER agonist Ph 2 Q-122 (Que Oncology) iVMS in BC on Tamoxifen or AIs CRCX4 modulator Ph 2 Fezolinetant (Astellas) VMS – Menopause NK3R antagonist Ph 3 NT-814 (KaNDy Therapeutics) VMS – Menopause
Slide 39: Osanetant Market Opportunity and IP
Acer acquired worldwide rights to osanetant from Sanofi in January 2019 Data from clinical proof of concept studies with other NK3R antagonists suggest rapid and potentially clinically meaningful improvement in vasomotor symptoms Ogeda SA was acquired by Astellas in 2017 for up to €800M Clinical and
Slide 40: Financial Overview
Cash: $23.5M as of June 30, 2019 Expected to have sufficient capital through end of 2020 Capitalization as of June 30, 2019: 10.1M shares of common stock outstanding 11.1M shares of common stock fully diluted $87M invested through August 2018 ACER Financial Overview Acer
Slide 41: Summary
Summary ACER Acer’s pipeline includes three clinical-stage product candidates: EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation ACER-001 (a fully taste-masked, immediate release formulation of sodium phe
Acer Therapeutics — Investor Presentation (October 2019) on 6ix